New Delhi: Shashvi Remedies, a Mumbai based pharmaceutical company, has claimed to have developed a new formulation with a successful game-changer potent to revolutionize the breast cancer treatment.
As per a press note issued by Shashvi, the company has under the visionary leadership of Founders Sonal Bansal, A K Bansal, and Co-Founders Birendra Singh Negi, Dr Kiran, Digant Sharma has contributed about ten years of rigorous research, development, and testing into perfecting this formulation.
According to recent research data released by WHO & Oncology research agencies, over 25% of the total cancers among females across the globe and over 30% in India are breast cancers. The report also suggests that the global rate of cancer cases is projected at 11.6% annually.
In order to successfully combat this rising rate of breast cancer, Shashvi Remedies has developed a clinically tested and world-class solution. This invention successfully passed the most important tests. In-Vitro on the MCF7 human breast cancer cell line was done in both 2018 and 2024. Results showed a killing of more than 80% cancerous cells within 72 hours and showed an excellent safety profile. The researched formulation is FSSAI approved: A bio-technology formulation with natural ingredients.
In further validation, an In-Vivo safety study conducted at Mumbai based reputed government Institute recorded a solution that was 100% safe on healthy cells to be considered an extraordinary development within cancer treatment.
“This formulation is safe and has the potential to save countless lives, after over a decade of rigorous research and testing, this achievement marks a triumph for the global medical community and, most importantly, for cancer patients worldwide. Our innovative approach specifically targets breast cancer cells without harming healthy tissue, and we hold the vision of developing a universal breast cancer vaccine, bringing us closer to a future where cancer is not only treatable but preventable. This breakthrough is a beacon of hope for breast cancer patients and their families and represents a significant step forward for the pharmaceutical industry as a whole,” said Sonal Bansal, Director and Spokesperson for Shashvi Remedies.
Dr Sagar Sengupta, Director, National Institute of Biomedical Genomics (NIBMG) and Director (Additional Charge), National Brain Research Centre (NBRC) shared his insights on the latest initiatives, importance of industry-academia collaboration, increased government funding, and evolution of research ecosystem
Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans